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BACKGROUND: Cav1.3 voltage-gated L-type calcium channels (LTCCs) are part of postsynaptic neuronal signaling
networks. They play a key role in brain function, including fear memory and emotional and drug-taking behaviors.
A whole-exome sequencing study identiﬁed a de novo mutation, p.A749G, in Cav1.3 α1-subunits (CACNA1D), the
second main LTCC in the brain, as 1 of 62 high risk–conferring mutations in a cohort of patients with autism and
intellectual disability. We screened all published genetic information available from whole-exome sequencing studies
and identiﬁed a second de novo CACNA1D mutation, p.G407R. Both mutations are present only in the probands and
not in their unaffected parents or siblings.
METHODS: We functionally expressed both mutations in tsA-201 cells to study their functional consequences using
whole-cell patch-clamp.
RESULTS: The mutations p.A749G and p.G407R caused dramatic changes in channel gating by shifting (15 mV)
the voltage dependence for steady-state activation and inactivation to more negative voltages (p.A749G) or by
pronounced slowing of current inactivation during depolarizing stimuli (p.G407R). In both cases, these changes are
compatible with a gain-of-function phenotype.
CONCLUSIONS: Our data, together with the discovery that Cav1.3 gain-of-function causes primary aldosteronism
with seizures, neurologic abnormalities, and intellectual disability, suggest that Cav1.3 gain-of-function mutations
confer a major part of the risk for autism in the two probands and may even cause the disease. Our ﬁndings have
immediate clinical relevance because blockers of LTCCs are available for therapeutic attempts in affected
individuals. Patients should also be explored for other symptoms likely resulting from Cav1.3 hyperactivity,
in particular, primary aldosteronism.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2014.11.020L-type calcium channels (LTCCs; Cav1) are one of the three
major classes (Cav1–Cav3) of voltage-gated calcium channels
(1). They are expressed in most electrically excitable cells
(1–3). Many body functions, including muscle contraction and
brain, endocrine, and sensory functions, depend on proper
LTCC activity (2–4). The LTCCs contain high-afﬁnity drug-
binding sites for different chemical classes of organic calcium
channel blockers (5). Blocking of LTCCs in vascular smooth
muscle and the heart has been therapeutically used for
decades to treat elevated blood pressure and cardiac ische-
mias. The dihydropyridine class of LTCC blockers still belongs
to the top-selling antihypertensives.
Despite their importance as peripheral drug targets, LTCCs
play a key role for normal brain function. Within the LTCC
family (Cav1.1–Cav1.4), Cav1.2 and Cav1.3 are the two
isoforms expressed in the brain (3). They are located at
postsynaptic somatodendritic sites, shape short-term and6 & 2015 Society of Biological Psychiatry
logical Psychiatry May 1, 2015; 77:816–822 www.sobp.org/journal
SEE COMMENTAlong-term adaptations of synaptic function (2,4,6,7), and are
often present in the same neurons (6). However, despite high
structural homology, they differ with respect to their gating
properties and protein interaction partners (3). They contribute
differently to various brain functions, such as emotional and
drug-taking behaviors and different types of memory (2–4).
Cav1.3 comprises only 10% of the LTCCs in the brain (8),
but because of its more negative activation voltage range, it
can carry inward calcium currents at threshold voltages (9,10),
shaping neuronal ﬁring patterns and contributing to pace-
maker currents (2,6,7,11).
Data from mouse studies and human channelopathies
provide important insight into the potential role of Cav1.2
and Cav1.3 LTCCs in human brain disease. In genome-wide
association studies and exome sequencing studies, CAC-
NA1C has emerged as a new candidate gene for neuropsy-
chiatric disease, including bipolar disorder, major depression,ISSN: 0006-3223
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Psychiatryschizophrenia, and autism (12–15). Reduced Cav1.2 expres-
sion in the mouse forebrain results in anxiety-like behavior.
Decreased channel function may contribute to the pathophysi-
ology of anxiety in neuropsychiatric diseases (16). Timothy
syndrome is a rare multiorgan disorder resulting from Cav1.2
gain-of-function mutations (OMIM No. 601005) (17), and
surviving patients may also develop autism and epilepsy
(17). Knock-in mice expressing the human mutation replicate
autistic behavioral traits (18). Both gain and loss of Cav1.2
channel activity can lead to central nervous system
dysfunction.
In contrast, heterozygous loss of Cav1.3 channel function
does not result in a detectable phenotype in mice (3,19) and
humans (20). Instead, the speciﬁc acute activation of Cav1.3
induces depression-like behaviors (8) and leads to activation
of brain regions involved in anxiety and fear circuits (21). Gain-
of-function of this channel may also underlie neuropsychiatric
symptoms in humans. This possibility is further supported by
the description of two patients with two different germline
CACNA1D gain-of-function mutations (22,23). These muta-
tions caused a severe congenital multiorgan syndrome with
primary aldosteronism (22,23), seizures, and neurologic abnor-
malities (PASNA; OMIM No. 615474). Symptoms also included
global developmental delay and intellectual disability (23)
indicating that constitutively enhanced Cav1.3 activity inter-
feres with normal neuronal function and development (22,23).
In the present study, we show that one CACNA1D mutation
(p.A749G in Cav1.3 α1), which has been reported as 1 of 62
high risk–conferring mutations in a whole-exome sequencing
(WES) study of patients with sporadic autism and intellectual
disability (24), induces a strong increase in Cav1.3 channel
function. We screened WES data in patients with sporadic
autism for other CACNA1D de novo mutations and identiﬁed
p.G407R in another patient, for which we also demonstrate a
pronounced gain-of-function. Our data strongly support CAC-
NA1D as a recurrent risk gene for autism spectrum disorder
(ASD). Given the nature of the mutation, the severe congenital
disorder in two other patients, and the pathophysiologic
relationship to Timothy syndrome, our data strongly suggest
possibly a causal role of CACNA1D gain-of-function mutations
for ASD in these patients. This observation has immediate
clinical relevance because clinically used blockers of LTCCs
are available for immediate therapeutic intervention. Affected
patients should also be monitored for other symptoms
expected from Cav1.3 hyperactivity, in particular, primary
hyperaldosteronism and hypertension (22,23).METHODS AND MATERIALS
WES Data Analysis
Published studies reporting WES data from probands with
sporadic autism were examined for de novo mutations in
CACNA1D. Five studies (24–28) providing data on 980 pro-
bands were identiﬁed (Table S1 in Supplement 1). Two
mutations, p.A749G (A749G; NM_000720 reference sequence)
in proband 11872.p1 and p.G407R (G407R) in proband 12620.
p1 in the Simons Simplex Collection, were reported in two
separate studies (24,25). Both mutations were present in
the patient only and not in family members. Both were notBiologicareported as variants in the Exome Variant Server (http://evs
.gs.washington.edu), the Single Nucleotide Polymorphism
Database, and the 1000 Genomes Project. Both were also
conﬁrmed as the only CACNA1D de novo mutations in a
recent WES study including 2303 trios (which included the
aforementioned cohort) (29).
Complementary DNA Constructs
The human wild-type Cav1.3 channel α1-subunit (CACNA1D
gene, National Center for Biotechnology Information reference
sequence EU363339, long C-terminal splice variant) contain-
ing the alternative exons 8a and 42 was previously cloned into
pGFPminus vector (mammalian expression plasmid controlled
by cytomegalovirus promoter; it lacks a GFP tag) (30). The
A749G and G407R mutations were introduced into the human
Cav1.3 construct using standard polymerase chain reaction
approaches. Mutated constructs were veriﬁed by DNA
sequencing (Euroﬁns MWG Operon; Euroﬁns Genomics,
Ebersberg, Germany).
Electrophysiologic Recordings in tsA-201 Cells
Cell culture and transient expression of Cav1.3 constructs in
tsA-201 cells were performed as described elsewhere (31).
Whole-cell patch-clamp recordings were performed at room
temperature. Borosilicate glass electrodes were pulled (micro-
pipette puller; Sutter Instrument Company, Novato, California)
and ﬁre polished (MF-830 Microforge; Narashige, London,
United Kingdom) at a ﬁnal resistance of 1.5–2.5 MΩ. Cells
were recorded at a sampling rate of 2–5 kHz using an
Axopatch 200B ampliﬁer (Molecular Devices, Biberach,
Germany), digitized with Digitizer 1322A (Molecular Devices),
and recorded with pClamp 10.2 software (Molecular Devices).
The recording solution contained in mmol/L: bath—15 calcium
chloride, 10 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic
acid, 150 choline chloride, and 1 magnesium chloride,
adjusted to pH 7.4 with cesium hydroxide; intracellular—135
cesium chloride, 10 N-2-hydroxyethylpiperazine-N-2-ethane-
sulfonic acid, 10 cesium–ethylene glycol tetraacetic acid, 1
magnesium chloride, 4 mmol/L disodium adenosine 50-
triphosphate adjusted to pH 7.4 with cesium hydroxide.
Cells were held at a holding potential of 280 mV before a
step protocol of 25 msec or 50 msec to different voltages was
applied to determine the current-voltage relationship. Currents
were leak subtracted using a P/4 protocol. The voltage depen-
dence of inactivation was measured by applying a control test
pulse (20 msec to the voltage of maximal inward current [Vmax])
followed by 5-sec conditioning steps to various potentials and
a subsequent 20-msec test pulse to Vmax (30-sec recovery
between protocols). Inactivation was calculated as the ratio
between the current amplitudes of the test versus control
pulse. Estimates for changes in channel open probability or
single channel conductance were obtained as described
previously (22) by normalizing the ionic tail current after a
20-msec or 25-msec depolarizing pulse to the reversal
potential to the “on” gating current (QON) obtained in the same
pulse. Current-voltage curves were ﬁtted to the equation I 5
Gmax(V 2 Vrev)/{1 1 exp [2 (V 2 V.5)/k]}), where Vrev is the
reversal potential, V is the test potential, I is the peak current,
Gmax is the maximum conductance, V.5 is the half maximall Psychiatry May 1, 2015; 77:816–822 www.sobp.org/journal 817
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dependence of calcium conductance was ﬁtted according to
a Boltzman distribution G 5 Gmax/{1 1 exp [2 (V 2 V.5)/k]}.
Steady-state inactivation parameters were obtained by ﬁtting
the data to a modiﬁed Boltzmann equation: G 5 (1 2 Gmax)/
{1 1 exp[(V 2 V.5)/k]} 1 Gmax. To reduce noise in some experi-
ments, protocols were repeated up to ﬁve times and record-
ings were averaged. A junction potential of 29.3 mV was
calculated and ofﬂine subtracted as previously described (32).
Immunoblot Analysis
The tsA-201 cells were transfected and cultured as described
previously (31). Methods for membrane preparation and
immunoblot analysis are described in detail in Supplement 1.
Statistics
Data analysis was performed using pClampﬁt 10.2 (Molecular
Devices), SigmaPlot 12 (Systat Software GmbH, Erkrath,
Germany) or GraphPad Prism 5.1 software (GraphPad Soft-
ware, Inc, La Jolla, California). All values are presented as
mean 6 SEM for the indicated number of experiments (n)
except if stated otherwise. Data were analyzed by unpaired
Student t test, Mann-Whitney test, and one-way analysis of
variance followed by Bonferroni posttest or Kruskal-Wallis test
followed by Dunnʼs posttest as indicated for individual experi-
ments. Statistical signiﬁcance was set at p , .05.RESULTS
CACNA1D De Novo Mutations in WES Studies of
Patients with Autism
The two identiﬁed CACNA1D de novo mutations, A749G in
proband 11872.p1 and G407R in proband 12620.p1, were
absent in the parents (family 11872) (24) and in the parents and
an unaffected sibling (family 12620) (25). Only A749G was
classiﬁed as a high-risk ASD mutation in the original publica-
tion (24). In both probands, A749G was the only amino acid–
changing mutation. In patient 11872.p1, another risk mutation
of unknown functional relevance (splice site mutation in
KATNAL2) was reported (24). In proband 12620.p1, a synon-
ymous mutation in ADAMTSL1 was found. No large copy
number variations were reported in the two probands. No
other major phenotypes (e.g., seizure, hyperaldosteronism)
were reported (24,25). Nonverbal IQ was 65 for proband
11872.p1 (24).
Biophysical Properties of A749G and G407R
Data from previous mutational studies in Cav1 α1-subunits
(33,34) strongly suggested interference of both mutations with
Cav1.3 LTCC function. G407R (present in exon 8a, one of two
alternative exons) is identical to a Timothy syndrome mutation
in Cav1.2 α1-subunits (17). In addition, A749G is located
adjacent to p.I750M (I750M), a Cav1.3 mutation for which
we reported a pronounced gain-of-function (22). Analysis of
the two mutations in a homology model of the Cav1.3 α1-
subunit also predicted pronounced changes of the interaction
of the affected distal S6 helices with adjacent S6 helices of the
activation gate (G407R, A749G) and of the S4–S5 linker with818 Biological Psychiatry May 1, 2015; 77:816–822 www.sobp.org/jouthe voltage sensor (G407R) (Figure S1 in Supplement 1).
This analysis prompted us to introduce both mutations into
human Cav1.3 α1-subunits and express them in tsA-201 cells
together with α2δ1 and β3 accessory subunits, which form
most LTCC complexes in the brain (35). Western blots
revealed robust expression of intact α1-subunits, although
slightly higher and lower expression of the G407R and
A749G mutant proteins were observed, respectively (Figure
S2 in Supplement 1). Both mutations strongly affected channel
gating (Figures 1 and 2). A749G signiﬁcantly enhanced peak
current amplitudes (wild-type, 211.6 6 2.2 pA/pF, n = 17;
A749G, 230.5 6 5.8 pA/pF, n = 27; p , .0001, Mann-Whitney
test; wild-type controls from same transfection experiments)
(Figure 1A); this was not due to an increased surface
expression estimated by quantiﬁcation of the QON, which
was signiﬁcantly decreased in the mutant (QON [pA*ms] wild-
type, 170 6 26.8, n 5 28; A749G, 80.5 6 11.4, n 5 20;
p , .009). A749G also shifted steady-state activation and
inactivation voltage dependence (Figure 1B) of inward calcium
currents to more negative potentials (Table 1).
Depolarizations to the reversal potential revealed an
increased ratio of maximal tail current amplitude to integrated
QON (Itail/QON [msec
21]: wild-type, 11.1 6 1.1, n 5 28; A749G,
34.1 6 2.25, n 5 20; p , .0001 vs. wild-type, unpaired Student
t test). This ﬁnding is compatible with a higher channel open
probability or conductance or both, a feature previously
observed by us also for other Cav1.3 gain-of-function muta-
tions (22). In contrast to A749G, mutation G407R reduced
maximal current amplitudes (Figure 2A) and caused no change
in activation voltage dependence (Figure 2A and Table 1).
However, in contrast to A749G, G407R dramatically slowed
the inactivation time course during 5-sec depolarizations. At
the end of the 5-sec pulse to Vmax, only 5.12% 6 .98% (n 5
15) of maximal wild-type and 3.07% 6 .37% (n 5 6) of A749G
current remained, whereas 82.8% 6 .04% (n 5 13) of G407R
current persisted (p , .001 vs. wild-type, Mann-Whitney test)
(Figure 2B, inset). The failure of G407R currents to inactivate
prevented the measurement of steady-state inactivation
parameters. Despite reduced maximal current amplitudes
(Figure 2A), the slow inactivation resulted in larger absolute
current amplitudes during prolonged depolarization than in
wild-type Cav1.3 channels (Figure 2B). The absence of a
fast inactivating component (mediated by calcium-dependent
inactivation in Cav1.3) (9,36) suggests that calcium-dependent
and voltage-dependent inactivation were strongly weakened
by the mutation. The smaller current and QON amplitudes were
unlikely because of a lower expression of mutant channel
protein as demonstrated by Western blots (Figure S2 in
Supplement 1).
Because patients are heterozygous for both mutations, we
next tested if the gain-of-function phenotype is also main-
tained when wild-type channels are coexpressed with the
mutants by transfection of equal quantities of α1-subunit
cDNAs; as evident from Figures 1 and 2 and Table 1, this
was the case. For coexpression of wild-type with A749G, the
gain-of-function was driven by the much larger current ampli-
tude of the mutant shifting overall steady-state activation
to more negative voltages, such as for A749G alone. Com-
bined expression yielded an Itail/QON ratio in between wild-type
and A749G values (Itail/QON [msec
21]: wild-type 1 A749G,rnal
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Figure 1. Biophysical properties of A749G expressed in tsA-201 cells. (A) Calcium current voltage relationships for human wild-type and A749G and
A749G mutants coexpressed together with wild-type (WT 1 A749G, equal amounts of complementary DNA transfected for both constructs) in tsA-201 cells
as described in Methods and Materials. Sample traces of inward calcium currents measured during depolarizations to maximum voltage are also shown.
Current-voltage curves include only data for wild-type channels pooled from parallel recordings with mutants in the same transfections (six independent
transfections) to account for differences in expression levels between transfections. A749G cotransfected with wild-type (WT 1 A749G) resulted in
signiﬁcantly increased peak current amplitudes (for statistics and numbers, see Results). Statistics for gating parameters are summarized in Table 1.
(B) Steady-state activation (circles) and inactivation (squares) curves for wild-type and A749G were obtained as described in Methods and Materials. Means 6
SEM are illustrated. Wild-type, n 5 29 (nine transfections); A749G, n 5 27 (six transfections). Steady-state activation parameters for WT 1 A749G are given in
Table 1.
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analysis of variance, Bonferroni posttest). This ﬁnding is
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Table 1. Gating Properties of Cav1.3 α1-Subunit (CACNA1D) Mutations A749G and G407R Compared with Wild-Type Cav1.3
Channels
α1 Subunit
Activation Steady-State Inactivation
V.5 (mV) Slope (mV) Vrev (mV) n V.5 (mV) Slope (mV) Noninactivating (%) n
WT 22.55 6 1.05 8.92 6 .20 67.7 6 1.14 29 225.7 6 2.08 5.56 6 .23 14.4 6 3.12 18
A749G 212.3 6 .87a 7.14 6 .20a 60.3 6 .83a 27 241.1 6 1.07a 5.82 6 .18 9.43 6 1.49 14
WT 1 A749G 215.0 6 1.71a 6.52 6 .40a 59.8 6 1.66b 11 ND
G407R 26.58 6 1.41 7.90 6 .30 54.7 6 2.32a 13 ND
WT 1 G407R 28.15 6 2.00 8.07 6 .82 58.9 6 2.99b 9 ND
All values are mean 6 SE. Number of independent transfections was $2. Parameters were obtained after ﬁtting normalized (I/Imax) I–V
relationships or normalized steady-state inactivation curves as described in Methods and Materials. Statistical analysis was performed using one-
way analysis of variance and Bonferroni post hoc test (activation) or unpaired Student t test (steady-state inactivation) as indicated.
n, number of experiments; ND, not determined; V.5, half maximal activation/inactivation voltage; Vrev, reversal potential; WT, wild-type.
ap , .001 compared with WT.
bp , .01 compared with WT.
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to for G407R expressed alone, a large fraction of inward
calcium currents remained at the end of a 5-sec pulse to Vmax
(55.7 6 8.46, n 5 10; p , .05 vs. wild-type, not signiﬁcant vs.
G407R alone, Kruskal-Wallis test, Dunnʼs posttest). Reduced
current amplitude was unlikely because of reduced α1-subunit
protein expression (Figure S2 in Supplement 1). Compared
with wild-type, this mutant also induced enhanced calcium
transients when expressed in electrically excitable GLT-
myotubes (Figure S3 in Supplement 1). Taken together, our
data demonstrate that both mutations increase Cav1.3 chan-
nel activity even when expressed in the heterozygous state.DISCUSSION
Our novel functional data strongly argue for an important
(perhaps causal) role of Cav1.3 in the pathophysiology of ASD.
Two de novo missense mutations were reported among 2303
trios, showing CACNA1D as one of the genes with recurrent
mutations in ASD. We found that both mutations affect
evolutionary highly conserved regions in the channelʼs activa-
tion gate and disrupt normal channel activity by inducing a
pronounced gain of channel function. This potential pathoge-
netic role of Cav1.3 hyperactivity for brain disease is further
strengthened by previous ﬁnding of two other Cav1.3 channel-
activating mutations (e.g., I750M; see further on) reported to
cause PASNA, a severe syndrome with neurodevelopmental
deﬁcits and seizures at an early age (22,23). One of the
mutations investigated here, G407R, is identical to G403R in
related Cav1.2 channels that causes Timothy syndrome. Most
patients with Timothy syndrome also have autism (17), and
mice containing the human mutation replicate autistic behav-
ioral traits (18). In mice, short-term pharmacologic activation of
Cav1.3 induces depression-like behaviors; this is also com-
patible with a role of this channel in neuropsychiatric symp-
toms (8). Cav1.3 LTCCs have been shown to play a crucial role
in synapse formation and dendritic reﬁnement in mice (37,38).
Because many molecules whose mutations or polymorphisms
are associated with ASD play a role in neuronal development,
neuronal or synaptic differentiation, or synaptic signaling (39),
Cav1.3 channels can be regarded as another member of the
postsynaptic signaling cascade found to be affected in
patients with ASD. This idea is further supported by the fact820 Biological Psychiatry May 1, 2015; 77:816–822 www.sobp.org/jouthat Cav1.3 forms direct interactions with shank, a protein well
known to play a pathogenic role in ASD (39–41).
The two germline mutations previously identiﬁed in the two
patients with PASNA raise the clinically relevant question
about why such symptoms (including aldosteronism and
epilepsy) were not reported in the two patients with ASD
described in this study. Although the number of mutations for
an extensive genotype-phenotype correlation is not yet large
enough, it is possible that different activating CACNA1D
mutations can induce a disease spectrum of different clini-
cal manifestations, as reported for mutations in Cav2.1
(CACNA1A) (42). It can be predicted that the mutational
consequences on channel function strongly depend on the
ﬁring pattern of neurons. For example, a shift of steady-state
inactivation to more negative voltages may reduce the channel
availability in neurons with depolarized membrane potentials,
such as dopamine neurons in the substantia nigra or ventral
tegmental area. This shift may also reduce the impact of other
gating changes promoting calcium inﬂux. Mutant mice
expressing Cav1.3 gain-of-function mutations are required to
conﬁrm this hypothesis.
Mutations can increase Cav1.3 calcium current activity
through different biophysical mechanisms as exempliﬁed by
the two mutants studied here and in somatic gain-of-function
mutations characterized in aldosterone-producing adenomas
(22,23). On the macroscopic current level, they can induce
channel activation and inactivation gating at more negative
voltages, such as A749G, or reduce channel inactivation
during depolarizing stimuli, such as G407R (reported here) or
P1336R (23). I750M is located adjacent to A749G and was one
of the mutations causing PASNA (23). I750M channels com-
bine the features of A749G and G407R because I750M not
only displays a more negative activation and inactivation
voltage range (similar to A749G) but also strongly slows
inactivation (similar to G407R) and does not decrease overall
current amplitude (23). This stronger functional change could
easily explain its more severe clinical consequences in
patients with PASNA; this is further supported by the similar
biophysical changes observed for the other PASNA mutation,
G403D (23). One could envisage that “mild” Cav1.3 gain-
of-function (as proposed in the two mutations analyzed
here) causes or strongly predisposes to the development of
ASD, whereas “strong” gain-of-function leads to PASNA withrnal
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seizures manifesting soon after birth.
In conclusion, our ﬁndings have immediate relevance for
clinical practice. In contrast to Cav1.2, Cav1.3 is not
expressed in ventricular cardiomyocytes (43). Cav1.3 activat-
ing mutations are not expected to cause long QT syndrome, a
frequent cause of early cardiac death in patients with Timothy
syndrome (17). Because Cav1.3 is expressed in the sinoatrial
node and atrial myocytes, supraventricular cardiac symptoms
may occur in carriers of activating Cav1.3 mutations. These
may also cause primary aldosteronism and hypertension with
or without hyperkalemia (23). Taken together, these data
provide a strong rationale for close monitoring of the two
patients with ASD for such symptoms throughout life. Clinical
studies in humans have shown that most available dihydro-
pyridine LTCC blockers used to treat hypertension also
permeate the blood-brain barrier and can affect neuronal
plasticity (44). Similar to Cav1.3 deﬁciency in mice, this does
not cause unwanted central nervous system side effects in
treated individuals. Safety has been conﬁrmed in a phase II
study with isradipine (which, similar to other dihydropyridines,
blocks both Cav1.2 and Cav1.3 channels) in preparation for
ongoing trials for neuroprotection in patients with Parkinson’s
disease (phase III, ClinicalTrials.gov Identiﬁer: NCT02168842)
and as adjunct therapy in patients with bipolar depression
(phase II, ClinicalTrials.gov Identiﬁer: NCT01784666). Inhibition
of LTCCs in the brain may ameliorate psychiatric symptoms in
the carriers of Cav1.3-activating CACNA1D mutations identi-
ﬁed in our study. Given the excellent toxicity proﬁle of
dihydropyridine LTCC blockers, long-term off-label treatment
of patients with ASD appears justiﬁed based on our robust
in vitro ﬁndings. Given enhanced depression-like behaviors in
mice after selective Cav1.3 LTCC activation (8,21), CACNA1D
should also be examined as a possible risk gene for depres-
sion and anxiety disorders in humans.
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